3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine | 1313237-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 3-(chloromethyl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine
• CAS: 1313237-29-4
• 化学式: C₁₅H₁₃ClN₂O₂S
• 分子量: 320.799
• InChiKey: SZAGUPPZCDMYGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 在 盐酸 、 正丁基锂 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 5.5h， 生成 methyl (S)-2-acetamido-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propionate
  参考文献：
  名称：

  Tryptophan-based fluorophores for studying protein conformational changes

  摘要：

  With the continuing interest in deciphering the interplay between protein function and conformational changes, small fluorescence probes will be especially useful for tracking changes in the crowded protein interior space. Presently, we describe the potential utility of six unnatural amino acid fluorescence donors structurally related to tryptophan and show how they can be efficiently incorporated into a protein as fluorescence probes. We also examine the various photophysical properties of the new Trp analogues, which are significantly redshifted in their fluorescence spectra relative to tryptophan. In general, the Trp analogues were well tolerated when inserted into Escherichia coli DHFR, and did not perturb enzyme activity, although substitution for Trp22 did result in a diminution in DHFR activity. Further, it was demonstrated that D and E at position 37 formed efficient FRET pairs with acridon-2-ylalanine (Acd) at position 17. The same was also true for a DHFR construct containing E at position 79 and Acd at position 17. Together, these findings demonstrate that these tryptophan analogues can be introduced into DHFR with minimal disruption of function, and that they can be employed for the selective study of targeted conformational changes in proteins, even in the presence of unmodified tryptophans. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.09.015
• 作为产物：
  描述：

  7-氮杂吲哚-3-甲醛 在 sodium tetrahydroborate 、 氯化亚砜 、 sodium hydride 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.17h， 生成 3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Tryptophan-based fluorophores for studying protein conformational changes

  摘要：

  With the continuing interest in deciphering the interplay between protein function and conformational changes, small fluorescence probes will be especially useful for tracking changes in the crowded protein interior space. Presently, we describe the potential utility of six unnatural amino acid fluorescence donors structurally related to tryptophan and show how they can be efficiently incorporated into a protein as fluorescence probes. We also examine the various photophysical properties of the new Trp analogues, which are significantly redshifted in their fluorescence spectra relative to tryptophan. In general, the Trp analogues were well tolerated when inserted into Escherichia coli DHFR, and did not perturb enzyme activity, although substitution for Trp22 did result in a diminution in DHFR activity. Further, it was demonstrated that D and E at position 37 formed efficient FRET pairs with acridon-2-ylalanine (Acd) at position 17. The same was also true for a DHFR construct containing E at position 79 and Acd at position 17. Together, these findings demonstrate that these tryptophan analogues can be introduced into DHFR with minimal disruption of function, and that they can be employed for the selective study of targeted conformational changes in proteins, even in the presence of unmodified tryptophans. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.09.015

文献信息

• Diaza-spiro[5.5]undecanes
  申请人：BADIGER Sangamesh

  公开号：US20120101110A1

  公开（公告）日：2012-04-26

  The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及具有公式I的化合物，其中取代基如说明书中所定义；以自由形式或盐形式存在；其制备方法，用作药物的使用，以及包含它的药物。
• [EN] DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DIAZA-SPIRO[5.5]UNDÉCANES EN TANT QU'ANTAGONISTES DE RÉCEPTEURS D'OREXINE
  申请人：NOVARTIS AG

  公开号：WO2011076747A1

  公开（公告）日：2011-06-30

  The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及公式(I)的化合物，其中取代基如说明书中所定义；以自由形式或盐形式；其制备方法，用作药物及其药物组合物。
• [EN] DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DIAZASPIRO[5.5]UNDÉCANES UTILES COMME ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：NOVARTIS AG

  公开号：WO2012055888A1

  公开（公告）日：2012-05-03

  The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及公式(I)的化合物，其中取代基如说明书中所定义；以自由形式或盐形式存在；涉及其制备方法、作为药物的应用，以及包含它的药物。
• DIAZA-SPIRO[5.5]UNDECANES
  申请人：Badiger Sangamesh

  公开号：US20120264748A1

  公开（公告）日：2012-10-18

  The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及式(I)的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其用作药物及包含其的药物。
• DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Badiger Sangamesh

  公开号：US20130281463A1

  公开（公告）日：2013-10-24

  The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及公式（I）的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备，其作为药物的使用以及包含它的药物。